Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)

13. november 2026 opdateret af: University Hospital, Clermont-Ferrand

Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.

Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.

Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:

  • Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
  • Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.

The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.

The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.

Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

700

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Angers, Frankrig, 49000
        • CHU d'Angers
        • Ledende efterforsker:
          • Antoine POIRIER
      • Clermont-Ferrand, Frankrig, 63000
      • Dijon, Frankrig, 21000
        • CHU de DIJON
        • Ledende efterforsker:
          • Fabien GARNIER

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
  2. Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
  3. Patients implanted with a self-expanding or balloon-expandable valve.
  4. Age ≥ 18 years.
  5. TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
  6. Life expectancy > 1 year.
  7. Affiliation to a social security scheme
  8. Written informed consent provided before study enrollment.

Exclusion Criteria:

  1. Permanent pacemaker implantation (PPI) before TAVI.
  2. Complete atrioventricular block after TAVI leading to immediate PPI.
  3. Permanent pacemaker implantation after TAVI for another indication (non-protocol).
  4. Pre-existing LBBB before TAVI.
  5. Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
  6. Pregnancy or breastfeeding.
  7. No affiliation to a social security scheme.
  8. Refusal to participate or withdrawal of informed consent.
  9. Incapacity to consent.
  10. Adults under legal protection (trusteeship, guardianship, curatorship).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)

LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing.

Andet: Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)

Control arm

ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary.

The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
Tidsramme: From randomization to 12 follow up

The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:

  1. Hospitalization for worsening heart failure,
  2. Episode of syncope or dizziness,
  3. High-grade atrioventricular conduction disturbance (second-degree AV block type II or third-degree AV block requiring implantation of a permanent pacemaker, documented > 3 seconds on ILR or ECG)).

The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk.

From randomization to 12 follow up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
Tidsramme: At 6,12, 24 and 36 months after randomization
At 6,12, 24 and 36 months after randomization
Evolution of LVEF
Tidsramme: At 6,12, 24 and 36 months after randomization

Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point.

At 6,12, 24 and 36 months after randomization
Evolution of Quality of life (EQ-5D)
Tidsramme: At 6, 12, 24 and 36 months after randomization

Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point.

At 6, 12, 24 and 36 months after randomization
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
Tidsramme: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Incidence of Mortality (all-cause, cardiovascular, HF-related)
Tidsramme: At 6, 12, 24 and 36 months after randomization

Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death.

At 6, 12, 24 and 36 months after randomization
Medico-economic evaluation
Tidsramme: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Complications related to pacemaker or ILR implantation
Tidsramme: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Unscheduled pacemaker implantation in the ILR group
Tidsramme: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. oktober 2026

Primær færdiggørelse (Anslået)

15. oktober 2033

Studieafslutning (Anslået)

15. oktober 2034

Datoer for studieregistrering

Først indsendt

6. oktober 2026

Først indsendt, der opfyldte QC-kriterier

26. oktober 2026

Først opslået (Faktiske)

2. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RBHP 2025 ESCHALIER 2

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .